Selank Research Peptide: What Preclinical Studies Reveal About This Synthetic Tuftsin Analogue
Published by the Elite Biologix Research Team — Compiled by clinical pharmacists with 27+ years of sterile compounding experience. Independent research compilation for scientific and educational reference only.
Key Takeaways
- Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a synthetic heptapeptide built on the tuftsin tetrapeptide core, extended with a Pro-Gly-Pro stabilizing sequence that substantially prolongs biological half-life relative to native tuftsin in preclinical models (Zozulya et al., Bulletin of Experimental Biology and Medicine, 2001, PMID: 11550013).
- Selank inhibited enkephalin-degrading enzymes dose-dependently with an IC50 of 15 µM in vitro — exceeding the potency of classical inhibitors bacitracin and puromycin (Zozulya et al., 2001, PMID: 11550013).
- A single intranasal dose of Selank increased BDNF mRNA levels in rat hippocampus at 3 hours and BDNF protein levels at 24 hours in controlled rodent studies (Inozemtseva et al., Doklady Biological Sciences, 2008, PMID: 18841804).
- As of 2026, Selank is not approved for human use by the FDA or any major international regulatory authority. All mechanistic data derives from in vitro assays and controlled animal models.
The Selank research literature occupies a distinctive niche in the preclinical neuropeptide field. Developed at the Institute of Molecular Genetics of the Russian Academy of Sciences — the same research program responsible for Semax — Selank has accumulated a substantive body of peer-reviewed preclinical data spanning enkephalin system pharmacology, GABAergic gene expression, BDNF neurotrophin induction, cytokine modulation, and behavioral endpoints in multiple rodent model paradigms.
What distinguishes Selank from many research peptides is the mechanistic specificity of its published data. Multiple independent Russian research groups have investigated the same compound across different biological systems, providing cross-institutional evidence for its preclinical profile. This article reviews that published literature — what the data shows, what it doesn't, and why Selank has remained an active subject of preclinical investigation for over two decades.
What Is Selank? Structure, Tuftsin Origin, and Stability Profile
Selank inhibited enkephalin-degrading enzymes in plasma preparations with an IC50 of 15 µM — exceeding the potency of the classical enzymatic inhibitors bacitracin and puromycin — in the 2001 foundational study that characterized its biochemical mechanism in vitro (Zozulya et al., Bulletin of Experimental Biology and Medicine, 2001, PMID: 11550013). This enkephalinase inhibition profile, established before most downstream behavioral studies, remains the biochemically best-characterized aspect of Selank's mechanism of action.
The compound's full sequence — Thr-Lys-Pro-Arg-Pro-Gly-Pro — consists of the tuftsin tetrapeptide core (Thr-Lys-Pro-Arg, a naturally occurring immunomodulatory peptide found as a fragment of IgG) followed by a Pro-Gly-Pro C-terminal extension. That extension is structurally analogous to the stabilizing tripeptide used in Semax, conferring resistance to peptidase degradation and substantially extending the biological half-life relative to native tuftsin, which is degraded within seconds in plasma. Selank acts at phagocyte receptors on monocytes and macrophages (the tuftsin receptor pathway), while the Pro-Gly-Pro metabolite retains independent biological activity in the CNS — creating a mechanistic parallel with Semax's dual parent-compound/metabolite activity model.
Research note: The strain-specific behavioral response to Selank identified in the 2002 Sokolov study is a methodological detail rarely discussed in secondary literature but scientifically important. BALB/c mice showed significant anxiolytic effects and extended leu-enkephalin half-life following Selank administration; C57Bl/6 mice showed neither effect (Sokolov et al., PMID: 12432865). This strain selectivity has direct implications for research design: studies using C57Bl/6 mice may systematically underestimate or miss Selank's behavioral effects. Researchers designing anxiety model studies with Selank should pre-specify mouse strain as a primary experimental variable.
Elite Biologix supplies Selank at ≥98% purity, verified by third-party batch testing with a published Certificate of Analysis, specifically for use in qualified research environments. View our Selank research compound.
Enkephalin System Pharmacology: The Primary Biochemical Mechanism
In 2001, Zozulya and colleagues at the Center of Mental Health (Russian Academy of Medical Sciences, Moscow) published the first characterization of Selank's biochemical mechanism: dose-dependent inhibition of enkephalin-degrading enzymes in plasma with IC50 = 15 µM, surpassing classical inhibitors bacitracin and puromycin in potency (PMID: 11550013). A companion behavioral study in BALB/c mice confirmed the functional consequence of this enzymatic inhibition — Selank at 100 µg/kg significantly increased plasma leu-enkephalin half-life and produced anxiolytic effects in the open-field test (Sokolov et al., 2002, PMID: 12432865).
The proposed mechanism is straightforward: by inhibiting the enzymes that degrade endogenous enkephalins (particularly dipeptidyl peptidase IV and aminopeptidase N), Selank prolongs the half-life of endogenous opioid peptides in circulation and at CNS receptor sites. Sustained enkephalin signaling at µ- and δ-opioid receptors in limbic structures is associated with reduced anxiety-related behavior in rodent models — a well-characterized preclinical anxiolytic mechanism that distinguishes enkephalin-based approaches from direct GABA-A receptor modulation.
| Compound | Enkephalinase Inhibition IC50 | Notes |
|---|---|---|
| Selank | 15 µM | Most potent inhibitor tested; dose-dependent in vitro |
| Puromycin | ~10 mM (estimated) | Classical reference inhibitor; less potent than Selank |
| Bacitracin | Higher than puromycin | Classical reference inhibitor; least potent of three |
| Source: Zozulya et al., Bulletin of Experimental Biology and Medicine, 2001 (PMID: 11550013). In vitro plasma preparation assay. | ||
This enkephalinase inhibition mechanism is mechanistically distinct from benzodiazepine-class anxiolytics (which act as direct GABA-A positive allosteric modulators) and from SSRIs (which inhibit serotonin reuptake). The opioid peptide half-life extension model places Selank in a unique pharmacological category among anxiolytic research compounds.
GABAergic Gene Expression: Transcriptomic Evidence in Rodent Frontal Cortex
In 2016, Volkova and colleagues used a custom PCR array to characterize Selank's effects on GABAergic neurotransmission gene expression in rat frontal cortex following intranasal administration (300 µg/kg). At 1 hour post-administration, Selank altered expression of 45 of 84 assayed genes; at 3 hours, 22 genes remained significantly altered (Volkova et al., Frontiers in Pharmacology, 2016, PMID: 26924987). Critically, the gene expression changes at 1 hour showed a statistically significant positive correlation with the effects of exogenous GABA itself — suggesting Selank's transcriptional profile mimics, rather than simply potentiates, GABAergic system activation.
This transcriptomic finding contextualizes earlier behavioral data. A 2017 study by Kasian and colleagues using a 14-day unpredictable chronic mild stress (UCMS) protocol in rats examined Selank (300 µg/kg intranasal) and diazepam (1 mg/kg oral), both alone and in combination. The combination produced an 8.9-fold increase in elevated plus-maze open-arm residence time versus saline-treated stressed controls — a magnitude of effect substantially exceeding either compound administered alone (Kasian et al., Behavioural Neurology, 2017, PMID: 28280289).
Research note: The 8.9-fold elevation in EPM open-arm time with the Selank-diazepam combination under UCMS conditions is a striking effect size for a preclinical anxiolytic study. However, it's essential to note what this finding does and doesn't demonstrate: it establishes that the combination produces an additive or supraadditive behavioral outcome in this specific stress model, not that either compound is clinically appropriate for anxiety disorders. The UCMS protocol itself varies substantially across laboratories, making direct cross-study comparisons difficult. This data is useful for researchers designing combination pharmacology studies, not for inferring clinical therapeutic potential.
BDNF Neurotrophin Induction in Rodent Hippocampus
In 2008, Inozemtseva and colleagues at the Institute of Molecular Genetics (Moscow) reported that a single intranasal administration of Selank produced a significant increase in BDNF mRNA levels in rat hippocampus at 3 hours post-dose, followed by elevated BDNF protein levels at 24 hours, as measured by RT-PCR and immunoenzyme assay respectively (Inozemtseva et al., Doklady Biological Sciences, 2008, PMID: 18841804). This temporal sequence — mRNA induction preceding protein elevation — is the expected pharmacokinetic profile for a transcriptional induction event and provides mechanistic plausibility for the observed BDNF protein changes.
The BDNF induction finding places Selank alongside Semax in the category of intranasal neuropeptides with documented neurotrophin-inducing activity in rodent hippocampus. [INTERNAL-LINK: Semax research article → companion neuropeptide with more extensively characterized BDNF-TrkB mechanism including TrkB phosphorylation data] The comparative mechanistic depth differs: Semax's BDNF data includes receptor-level TrkB phosphorylation quantification across multiple studies, while Selank's BDNF evidence rests on a single 2008 study without published TrkB downstream validation. Researchers designing neurotrophin-focused studies should account for this differential evidence depth.
A 2019 study by Kolik and colleagues extended the BDNF research in a different direction, demonstrating that Selank (0.3 mg/kg IP, 7 days) prevented ethanol-induced elevation of BDNF content in hippocampus and frontal cortex and protected against memory and attention deficits during alcohol withdrawal in the object recognition test (P < 0.05 and P < 0.01, respectively) (Kolik et al., Bulletin of Experimental Biology and Medicine, 2019, PMID: 31625062). This rodent model study demonstrates Selank's BDNF-regulatory effects in a specific pathological context rather than baseline physiology.
Anti-Inflammatory Cytokine Research in Animal Models
Selank's immunomodulatory profile — derived from its tuftsin core — has been characterized at both the genomic and protein level in animal models. A 2011 study by Kolomin and colleagues at the Institute of Molecular Genetics found that Selank (100 µg/kg IP) significantly altered expression of 34 of 84 assayed inflammation-related genes in mouse spleen at 6 and 24 hours post-injection, including the transcriptional repressor Bcl6 which regulates IL-6 signaling (Kolomin et al., Regulatory Peptides, 2011, PMID: 21609736).
Protein-level cytokine data was provided by Yasenyavskaya and colleagues (2021), who administered Selank (100 µg/kg/day IP) to rats under a 20-day social stress protocol. Selank normalized elevated IL-1β, IL-6, and TGF-β1 concentrations and suppressed TNF-α production, restoring all four cytokines to levels near unstressed control values (Yasenyavskaya et al., Current Reviews in Clinical and Experimental Pharmacology, 2021, PMID: 32621722).
| Research Area | Key Selank Finding | Primary Citation |
|---|---|---|
| Enkephalinase inhibition | IC50 15 µM in vitro; more potent than bacitracin and puromycin | PMID 11550013 (2001) |
| Enkephalin half-life | Extended leu-enkephalin half-life in BALB/c mice (strain-specific effect) | PMID 12432865 (2002) |
| Cognitive behavior | Reduced errors and increased correct responses in active avoidance test in rats with poor baseline learning (P < 0.05) | PMID 14552529 (2003) |
| BDNF induction | ↑BDNF mRNA at 3h, ↑BDNF protein at 24h in rat hippocampus after single intranasal dose | PMID 18841804 (2008) |
| GABAergic gene expression | 45 of 84 GABAergic genes altered at 1h; 22 at 3h; expression pattern correlates with exogenous GABA | PMID 26924987 (2016) |
| Anxiety behavior (combination) | 8.9-fold increase in EPM open-arm time vs. stressed controls (Selank + diazepam, UCMS model) | PMID 28280289 (2017) |
| BDNF / ethanol model | Prevented ethanol-induced BDNF elevation; protected memory/attention in withdrawal (P < 0.01) | PMID 31625062 (2019) |
| Cytokine normalization | Restored IL-1β, IL-6, TNF-α, TGF-β1 to near-control values under social stress in rats | PMID 32621722 (2021) |
| All findings from in vitro assays or controlled rodent model studies. Not validated in human clinical trials. | ||
The convergence of genomic data (34 inflammation-related genes in spleen) and protein-level cytokine normalization (IL-1β, IL-6, TNF-α, TGF-β1) across two independent research groups provides cross-institutional corroboration for Selank's anti-inflammatory preclinical profile. Both studies used the same dose range (100 µg/kg) and IP administration route, strengthening the mechanistic consistency.
How Does Selank Compare to Semax in Preclinical Research?
Selank and Semax share a research origin (Institute of Molecular Genetics, Moscow), a structural feature (Pro-Gly-Pro C-terminal stabilization), and a BDNF-inducing effect in rodent hippocampus. Their mechanistic profiles diverge significantly beyond these commonalities. [INTERNAL-LINK: Semax research article → companion neuropeptide with stronger ischemia neuroprotection evidence and more characterized BDNF-TrkB phosphorylation data]
Semax's published evidence base is deeper in neuroprotection (multiple MCAO rodent model studies, transcriptome-level ischemia data) and receptor pharmacology (established MC4R binding kinetics). Selank's published evidence base is more developed in anxiety-related behavioral endpoints (multiple EPM and open-field studies), the enkephalin system (the IC50 characterization has no Semax equivalent), and cytokine modulation under social stress models. The compounds appear to occupy complementary rather than overlapping research niches — a distinction useful for researchers selecting between them based on their specific study design requirements.
Elite Biologix supplies Selank at ≥98% purity, verified by third-party batch testing with a published Certificate of Analysis, specifically for use in qualified research environments. View our Selank research compound. For researchers investigating complementary neuropeptide mechanisms, [INTERNAL-LINK: Semax research article → MC4R/BDNF neuroprotection research compound] is also available from our catalog.
Frequently Asked Questions About Selank Preclinical Research
What is Selank and how does it differ structurally from native tuftsin?
Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a synthetic heptapeptide built on the tuftsin tetrapeptide core (Thr-Lys-Pro-Arg) with a Pro-Gly-Pro C-terminal extension. Native tuftsin is degraded within seconds in plasma by peptidases; the Pro-Gly-Pro extension in Selank blocks this cleavage, substantially extending biological half-life in rodent models. Selank retains tuftsin's immunomodulatory receptor activity while gaining CNS-accessible stability.
What is the primary biochemical mechanism identified for Selank in preclinical studies?
The most biochemically characterized Selank mechanism is inhibition of enkephalin-degrading enzymes (enkephalinases) with IC50 = 15 µM in plasma preparations — exceeding the potency of classical inhibitors bacitracin and puromycin (PMID: 11550013). By inhibiting these enzymes, Selank extends the half-life of endogenous leu-enkephalin in BALB/c mice (PMID: 12432865), sustaining opioid peptide signaling in limbic circuits associated with anxiety-related behavior in rodent models.
What BDNF data exists for Selank in animal models?
A single intranasal Selank dose (route/dose not specified in the abstract) increased BDNF mRNA in rat hippocampus at 3 hours and BDNF protein at 24 hours post-administration, as measured by RT-PCR and immunoenzyme assay (PMID: 18841804). A separate 2019 study found that repeated Selank administration (0.3 mg/kg IP, 7 days) prevented ethanol-induced BDNF dysregulation and protected cognitive performance during withdrawal in rodents (PMID: 31625062).
What does the GABAergic gene expression data show?
Intranasal Selank (300 µg/kg) altered 45 of 84 GABAergic neurotransmission-related genes in rat frontal cortex at 1 hour, with 22 remaining significantly altered at 3 hours (PMID: 26924987). The 1-hour expression pattern showed positive correlation with exogenous GABA's own gene expression effects — suggesting Selank's transcriptional profile resembles GABAergic system activation, though Selank is not a direct GABA-A agonist.
Is Selank approved for use in humans?
Selank is approved as an anxiolytic drug in Russia under limited regulatory authorization, but is not approved for human use by the FDA or any major Western regulatory authority. All mechanistic data cited in this article originates from in vitro biochemical assays and controlled animal model studies. Selank is sold exclusively for laboratory and research purposes.
Conclusion: Selank in the Preclinical Neuropeptide Research Landscape
The Selank preclinical literature is notable for its mechanistic breadth across multiple biological systems — enkephalin pharmacology, GABAergic transcriptomics, BDNF neurotrophin biology, and inflammatory cytokine regulation — with cross-institutional validation from at least four independent Moscow-area research groups spanning 2001 to 2021. This geographic concentration of research is both a strength (consistent methodology, shared model systems) and a limitation (limited independent Western replication, no large-scale controlled animal studies matching Western preclinical standards).
For researchers studying enkephalin system pharmacology, anxiety-related behavior in rodent models, or GABAergic gene expression, Selank's published profile provides a well-documented experimental tool with clearly characterized primary mechanisms. Researchers should note the strain specificity finding (BALB/c vs. C57Bl/6) when designing behavioral studies, and the single-study status of the BDNF data when designing neurotrophin-focused experiments. [INTERNAL-LINK: Semax research article → neuropeptide with complementary BDNF-TrkB and neuroprotection evidence base]
Elite Biologix supplies Selank at ≥98% purity, verified by third-party batch testing with a published Certificate of Analysis, specifically for use in qualified research environments. View our Selank research compound.
References
- Zozulya AA, Kost NV, Sokolov OYu, Gabaeva MV, Grivennikov IA, Andreeva LA, Myasoedov NF, Nesmeyanov VA. Inhibition of enkephalin-degrading enzymes by Selank. Bulletin of Experimental Biology and Medicine. 2001. PMID: 11550013.
- Sokolov OYu, Meshavkin VK, Kost NV, Zozulya AA. Effects of Selank on Behavioral Responses and Enkephalin-Degrading Enzyme Activity in BALB/c and C57Bl/6 Mice. Bulletin of Experimental Biology and Medicine. 2002. PMID: 12432865.
- Kozlovskii II, Danchev ND. The Optimizing Action of the Synthetic Peptide Selank on a Conditioned Active Avoidance Reflex in Rats. Neuroscience and Behavioral Physiology. 2003. PMID: 14552529.
- Inozemtseva LS, Dolotov OV, Grivennikov IA. Intranasal Administration of Selank Elevates BDNF mRNA and Protein in Rat Hippocampus. Doklady Biological Sciences. 2008. PMID: 18841804.
- Kolomin T, Shadrina M, Slominsky P, Limborska S, Myasoedov N. A New Generation of Drugs: Synthetic Peptides Based on Natural Regulatory Peptides. Regulatory Peptides. 2011. PMID: 21609736.
- Volkova A, Shadrina M, Kolomin T, Andreeva L, Myasoedov N, Slominsky P, Limborska S. Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission. Frontiers in Pharmacology. 2016. PMID: 26924987.
- Kasian A, Shevchenko K, Baskakova A, Shevchenko V, Andreeva L, Shram S, Myasoedov N. Behavioural Effects of Selank and Its Metabolite Thr-Lys-Pro-Arg-Pro (5-mer) and Combination with Diazepam. Behavioural Neurology. 2017. PMID: 28280289.
- Kolik LG, Nadorova AV, Pravdivtseva OE. Effect of Selank on Behavioral Changes Caused by Ethanol and Dynamics of BDNF in Brain Structures of Rats. Bulletin of Experimental Biology and Medicine. 2019. PMID: 31625062.
- Yasenyavskaya AL, Shakhbazov AV, Linkova NS, Kvetnoy IM, Samotrueva MA. Influence of Selank on the Level of Pro- and Anti-Inflammatory Cytokines in Conditions of Social Stress in Rats. Current Reviews in Clinical and Experimental Pharmacology. 2021. PMID: 32621722.
- Filatova EV, Shadrina MI, Slominsky PA, Myasoedov NF, Limborska SA. Influence of Selank on Expression of Genes Encoding Receptor Subunits of GABA in IMR-32 Cells. Frontiers in Pharmacology. 2017. DOI: 10.3389/fphar.2017.00089.
Selank is sold exclusively for laboratory and research purposes. It is not approved for human use by the FDA or any regulatory authority. All information presented in this article is derived from published preclinical research using in vitro assays and animal models. Findings from rodent studies cannot be presumed to translate directly to human physiology. Elite Biologix does not make any claims regarding the safety or efficacy of Selank for use in humans or animals.
